Eugene Zhukovsky
Keine laufenden Positionen mehr
Profil
Dr. Eugene Zhukovsky is Chief Scientific Officer & Member-Management Board at Affimed Therapeutics AG and Chief Scientific Officer at Affimed NV.
Dr. Zhukovsky was previously employed as a Principal by Xencor, Inc.
He received his graduate degree from the St. Petersburg University of Economics & Finance and a doctorate degree from Brandeis University.
Ehemalige bekannte Positionen von Eugene Zhukovsky
| Unternehmen | Position | Ende |
|---|---|---|
| AFFIMED N.V. | Technik-/Wissenschafts-/F&E-Leiter | 31.03.2014 |
| XENCOR, INC. | Corporate Officer/Principal | 01.01.2009 |
Affimed NV Niederlassung Deutschland
 Affimed NV Niederlassung Deutschland Pharmaceuticals: MajorHealth Technology Affimed NV Niederlassung Deutschland discovers and develops antibody-based therapeutic drugs. The firm generates and develops a pipeline of antibody product candidates based on proprietary technology platform. It offer therapeutic drugs that target autoimmune diseases and tumor cells. The company was founded in 2000 and is headquartered in Heidelberg, Germany. | Technik-/Wissenschafts-/F&E-Leiter | - |
Ausbildung von Eugene Zhukovsky
| Brandeis University | Doctorate Degree |
| Saint Petersburg State University of Economics | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| XENCOR, INC. | Health Technology |
| AFFIMED N.V. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Affimed NV Niederlassung Deutschland
Affimed NV Niederlassung Deutschland Pharmaceuticals: MajorHealth Technology Affimed NV Niederlassung Deutschland discovers and develops antibody-based therapeutic drugs. The firm generates and develops a pipeline of antibody product candidates based on proprietary technology platform. It offer therapeutic drugs that target autoimmune diseases and tumor cells. The company was founded in 2000 and is headquartered in Heidelberg, Germany. | Health Technology |
